exhibit 10. 1 sponsored research agreement addendum no. 7 ( termination ) june 30, 2017 this addendum is being entered into to modify the sponsored research agreement ( sra ) dated september 1, 2009 made by and between trauma research llc ( “ trllc ” ) and ampio pharmaceuticals, inc. ( the “ company ” or “ ampio ”, formerly dmi life sciences, inc. ) whereas, the sra was entered into as of september 1, 2009 ; and whereas, the sra has been amended and modified pursuant to addendum no. 1, thereto executed as of june 1, 2012, addendum no. 2 thereto executed as of june 15, 2013, addendum no. 3, dated as of september 1, 2013 and addendum no. 4, dated as of march 17, 2014 and addendum no. 5, dated as of march 31, 2014 ; and whereas, the parties agree that the previous research performed at trllc to date has discovered and elucidated critically important mechanism of actions ( moa ) of ampiontm for the treatment of osteoarthritis of the knee ( oak ) and published those studies in peer reviewed journals, in satisfaction of a key element of obtaining regulatory approval of the drug and acceptance by potential commercial partners of the company, and tm whereas the parties hereto ( “ the parties ) agree that now that the company has obtained fda agreement for a clinical trial design for a final pivotal study that, if successful, will provide the basis for the filing of a biologics license application ( bla ) for the commercialization of the drug, and whereas the two major tasks ahead for the company, which should be executed concurrently, are the managing of the final pivotal clinical trial, and the completion of the chemistry, manufacturing and controls ( cmc ) requirements of the fda, including the bio - assay that allows quality control release of ampiontm production lots, and tm whereas the effort to accomplish these two major tasks by the end of 2017 will require the company to focus all of its limited financial resources on the engagement of technical staff, or outside contractors, that possess the requisite skills and experience to perform these tasks successfully and rapidly, and whereas, both parties intend to explore a new set of research projects to be undertaken by trllc, and funded by ampio, once the ampiontm bla has been filed and